Peptide Comparison
UlaritidevsBPC-157
A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Ularitide
As prescribed–As prescribed mg
BPC-157
250–500 mcg
Frequency
Ularitide
Once daily
BPC-157
Once daily
Administration
Ularitide
Intravenous infusion
BPC-157
Subcutaneous injection
Cycle Length
Ularitide
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Ularitide
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Ularitide
Strong human trials (Phase 3 or FDA approved)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Cardiovascular Support
Fluid & Electrolyte Balance
Kidney Protection
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Ularitide
Molecular Formula
C145H234N52O44S3
Molecular Weight
3505.9
Half-Life
6-7 minutes (in circulation)
Bioavailability
100% (intravenous administration)
CAS Number
Not publicly assigned (proprietary compound)
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Ularitide
BPC-157
Applications
Best
suited for
Ularitide
Managing acute heart failure symptoms and fluid overload
Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving oxygen delivery when your heart can't pump efficiently
Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting kidney function in critical heart patients
Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Ularitide
Common
- Dizziness or lightheadedness
- Low blood pressure (hypotension)
- Headache
- Nausea
Uncommon
- Elevated potassium levels
- Worsening kidney function (transient)
- Allergic reactions at injection site
- Chest discomfort
- Irregular heartbeat (arrhythmia)
Serious
- Severe hypotension requiring intervention
- Worsening heart function in some patients
- Acute kidney injury (rare)
- Anaphylactic shock (very rare)
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Ularitide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Not FDA approved
Safety Overview
Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. Natriuretic peptide class risks include worsening renal function in some patients and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.
Contraindications
- xHypotension (dangerously low blood pressure)
- xCardiogenic shock without proper monitoring
- xSevere renal dysfunction in some cases
- xAllergy to synthetic peptides
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Ularitide if...
- Managing acute heart failure symptoms and fluid overload
- Improving oxygen delivery when your heart can't pump efficiently
- Protecting kidney function in critical heart patients
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health